
|Videos|November 3, 2017
Dr. Stadtmauer on Current Challenges With Multiple Myeloma
Author(s)Edward A. Stadtmauer, MD
Advertisement
Edward A. Stadtmauer, MD, section chief of Hematologic Malignancies, Abramson Cancer Center, University of Pennsylvania, discusses the current challenges with multiple myeloma.
The biggest challenge with multiple myeloma is understanding which combinations or sequences to use with these field-changing agents, explains Stadtmauer.
Ongoing trials are helping oncologists understand more about when and how long to treat patients with these agents. Stadtmauer says he is hopeful about the outcome for patients with multiple myeloma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5



































